Free Trial
NASDAQ:INBX

Inhibrx 11/9/2023 Earnings Report

Inhibrx logo
$13.75 +0.84 (+6.51%)
Closing price 04:00 PM Eastern
Extended Trading
$13.69 -0.06 (-0.44%)
As of 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx EPS Results

Actual EPS
-$1.10
Consensus EPS
-$1.01
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Inhibrx Revenue Results

Actual Revenue
$0.12 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inhibrx Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Inhibrx's Q4 2024 earnings is scheduled for Monday, June 16, 2025

Conference Call Resources

Inhibrx Earnings Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Inhibrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibrx and other key companies, straight to your email.

About Inhibrx

Inhibrx (NASDAQ:INBX), a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

View Inhibrx Profile

More Earnings Resources from MarketBeat